CYP2C19 and liver disorder: PNPLA3 is an established genetic marker of progressive liver disease (Dubuquoy et al., 2013), but PNPLA3 mRNA expression did not correlate to CYP2C19 activity in this cohort (r = 0.07, p = 0.68, Figure 2E).